Psoriasis Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Psoriasis Drugs Market Report is Segmented by Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, and Tropical Therapies), Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, and Other Mechanisms of Action), Route of Administration (Oral, Parenteral, and Topical), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (USD Million) for the Above Segments.

Psoriasis Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Global Psoriasis Drugs Market Size

Global Psoriasis Drugs Market Summary
Study Period 2020 - 2030
Market Size (2025) USD 20 Billion
Market Size (2030) USD 30.32 Billion
CAGR (2025 - 2030) 8.68 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Global Psoriasis Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Psoriasis Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Global Psoriasis Drugs Market Analysis

The Global Psoriasis Drugs Market size is estimated at USD 20 billion in 2025, and is expected to reach USD 30.32 billion by 2030, at a CAGR of 8.68% during the forecast period (2025-2030).

The market's growth is primarily due to an increasing disease burden and demand for psoriasis medicines in emerging economies and an increase in psoriasis research and pipeline drugs.

The high burden of psoriasis worldwide is expected to boost the demand for its drugs, thus contributing to market growth. For instance, the data published by the National Psoriasis Foundation in August 2024 mentioned that over 8 million individuals in the United States and 125 million across the globe were affected by psoriasis in 2023. Thus, such a high burden of psoriasis among the population is anticipated to fuel the demand for psoriasis drugs and is expected to propel the market growth

Novel drugs with oral administration are opening avenues for needle-averse patients. For instance, in November 2024, Johnson & Johnson Services, Inc. showcased interim findings from the PsABIOnd study, which evaluated the effects of TREMFYA and IL-17 inhibitors on how patients perceive the impact of psoriatic arthritis (PsA). The study revealed significant reductions in joint pain, skin symptoms, and overall disease activity, underscoring the beneficial effects of TREMFYA on PsA. Additionally, in September 2024, Bristol Myers Squibb introduced positive results from the Phase 3b/4 PSORIATYK SCALP trial, which assessed the efficacy of Sotyktu (deucravacitinib) for treating patients with moderate to severe scalp psoriasis, even in those with milder overall psoriasis. The trial also achieved important secondary endpoints at week 16, revealed that a significantly more significant percentage of patients experienced at least a 90% improvement in their psoriasis. Thus, key market players are involved in various business strategies, such as product approvals and positive clinical trials, to expand their product portfolios and gain a competitive edge, which is anticipated to boost market growth.

Therefore, the market is expected to register a high growth rate during the forecast period due to the abovementioned factors, such as the high burden of psoriasis and the market player initiatives. However, the adverse side effects of most of the existing medications and the high cost of treatment are expected to hamper the market's growth.

Global Psoriasis Drugs Industry Overview

The psoriasis drugs market is moderately competitive and consists of several key players. Concerning the market share, few of the key players currently dominate the market. Companies are focusing on business expansion in developing regions or emerging markets, such as India, China, and South Korea, by adopting strategies, including alliances and acquisitions, to develop novel products. Some of the major players operating in the market include Johnson and Johnson Services Inc., Pfizer Inc., Amgen Inc., Eli Lilly and Company, and Novartis AG, among others.

Global Psoriasis Drugs Market Leaders

  1. Eli Lilly and Company

  2. Pfizer Inc.

  3. Novartis AG

  4. Amgen Inc.

  5. Johnson & Johnson Services, Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Global Psoriasis Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Global Psoriasis Drugs Market News

  • November 2024: UCB S.A. presented new two-year data validating a continuous clinical response for bimekizumab-bkzx, an inhibitor of IL-17A and IL-17F, in adults diagnosed with active psoriatic arthritis (PsA) with observable signs of reduction in inflammation.
  • September 2024: Organon and Dermavant Sciences Ltd. finalized an agreement in which Organon will acquire Dermavant, a company under Roivant that specializes in the development and commercialization of cutting-edge therapeutics for immuno-dermatology. Dermavant's innovative product approved by the United States Food and Drug Administration (FDA), VTAMA (tapinarof) cream, 1%, for the topical treatment of adults with mild, moderate, and severe plaque psoriasis. By combining Dermavant’s robust dermatology commercial and field medical teams in the United States with Organon’s capabilities in market access, regulatory proficiency, and global commercial presence.

Global Psoriasis Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies
    • 4.2.2 Increasing Use of Combination Therapies
    • 4.2.3 Increase in Psoriasis Research and Pipeline Drugs
  • 4.3 Market Restraints
    • 4.3.1 Adverse Side Effects of Existing Medications
    • 4.3.2 High Cost of Psoriasis Treatments
    • 4.3.3 Extensive Drug Development and Approval Process
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Type of Treatment
    • 5.1.1 Biologic Drugs
    • 5.1.2 Small Molecule Systemic Drugs
    • 5.1.3 Tropical Therapies
  • 5.2 By Mechanism of Action
    • 5.2.1 TNF Alpha Inhibitors
    • 5.2.2 PDE4 Inhibitors
    • 5.2.3 Interleukin Inhibitors
    • 5.2.4 Other Mechanisms of Action
  • 5.3 By Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Parenteral
    • 5.3.3 Topical
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 AstraZeneca
    • 6.1.4 Boehringer Ingelheim
    • 6.1.5 Celgene Corporation
    • 6.1.6 Dr.Reddy`s Laboratories
    • 6.1.7 Eli Lilly and Company
    • 6.1.8 Forward Pharma A/S
    • 6.1.9 Johnson and Johnson Services, Inc.
    • 6.1.10 Leo Pharma A/S
    • 6.1.11 Merck and Co. Inc.
    • 6.1.12 Novartis AG
    • 6.1.13 Pfizer Inc.
    • 6.1.14 Stiefel Laboratories Inc.
    • 6.1.15 Sunpharmaceutical Industries Limited
    • 6.1.16 Takeda Pharmaceutical Company Limited
    • 6.1.17 UCB SA
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Psoriasis Drugs Industry Segmentation

As per the scope of the report, psoriasis is a genetic condition that may or may not be present at birth but can also be triggered by certain environmental and genetic factors. Factors such as the changing lifestyles of people and their increased inclination toward alcohol consumption and smoking, unhealthy diets, and sedentary living are making people more prone to this condition. The psoriasis drugs market is segmented by type of treatment, mechanism of action, route of administration and geography. By type of treatment, the market is segmented into biologic drugs, small molecule systemic drugs, and tropical therapies. By mechanism of action, the market is segmented into TNF alpha inhibitors, PDE4 inhibitors, interleukin inhibitors, and other mechanisms of action. Other mechanism of action will include anti CD-6 monoclonal antibodies, JAK inhibitors and others. By route of administration, the market is segmented into oral, parenteral, and topical. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.

By Type of Treatment Biologic Drugs
Small Molecule Systemic Drugs
Tropical Therapies
By Mechanism of Action TNF Alpha Inhibitors
PDE4 Inhibitors
Interleukin Inhibitors
Other Mechanisms of Action
By Route of Administration Oral
Parenteral
Topical
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Global Psoriasis Drugs Market Research FAQs

How big is the Global Psoriasis Drugs Market?

The Global Psoriasis Drugs Market size is expected to reach USD 20 billion in 2025 and grow at a CAGR of 8.68% to reach USD 30.32 billion by 2030.

What is the current Global Psoriasis Drugs Market size?

In 2025, the Global Psoriasis Drugs Market size is expected to reach USD 20 billion.

Who are the key players in Global Psoriasis Drugs Market?

Eli Lilly and Company, Pfizer Inc., Novartis AG, Amgen Inc. and Johnson & Johnson Services, Inc. are the major companies operating in the Global Psoriasis Drugs Market.

Which is the fastest growing region in Global Psoriasis Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Psoriasis Drugs Market?

In 2025, the North America accounts for the largest market share in Global Psoriasis Drugs Market.

What years does this Global Psoriasis Drugs Market cover, and what was the market size in 2024?

In 2024, the Global Psoriasis Drugs Market size was estimated at USD 18.26 billion. The report covers the Global Psoriasis Drugs Market historical market size for years: 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Psoriasis Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.